Ascendis Pharma A/S (NASDAQ:ASND) Receives Average Rating of “Buy” from Brokerages

Ascendis Pharma A/S (NASDAQ:ASND) has received an average recommendation of “Buy” from the twelve ratings firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $136.88.

ASND has been the subject of a number of analyst reports. Zacks Investment Research lowered shares of Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research report on Monday, August 5th. Wedbush restated a “buy” rating and issued a $223.00 price objective on shares of Ascendis Pharma A/S in a research report on Friday, June 28th. Canaccord Genuity raised their price objective on shares of Ascendis Pharma A/S from $133.00 to $144.00 and gave the company a “buy” rating in a research report on Friday, May 31st. Finally, BidaskClub lowered shares of Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a research report on Monday, June 24th.

Shares of ASND stock traded up $0.68 during trading hours on Wednesday, reaching $116.20. The stock had a trading volume of 633,500 shares, compared to its average volume of 334,036. The stock’s fifty day simple moving average is $114.64 and its 200 day simple moving average is $111.26. The company has a current ratio of 22.32, a quick ratio of 22.32 and a debt-to-equity ratio of 0.02. Ascendis Pharma A/S has a 12 month low of $53.21 and a 12 month high of $133.96. The firm has a market capitalization of $4.87 billion, a PE ratio of -31.07 and a beta of 0.62.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Thursday, May 30th. The biotechnology company reported ($1.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.44). Ascendis Pharma A/S had a negative net margin of 901.89% and a negative return on equity of 34.64%. The firm had revenue of $6.15 million during the quarter, compared to the consensus estimate of $0.66 million. As a group, equities research analysts anticipate that Ascendis Pharma A/S will post -5.46 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD raised its stake in Ascendis Pharma A/S by 53.7% in the second quarter. Price T Rowe Associates Inc. MD now owns 7,178,036 shares of the biotechnology company’s stock valued at $826,551,000 after purchasing an additional 2,509,034 shares in the last quarter. FMR LLC raised its stake in Ascendis Pharma A/S by 11.6% in the first quarter. FMR LLC now owns 4,692,707 shares of the biotechnology company’s stock valued at $552,332,000 after purchasing an additional 489,461 shares in the last quarter. Vivo Capital LLC raised its stake in Ascendis Pharma A/S by 0.6% in the second quarter. Vivo Capital LLC now owns 2,060,135 shares of the biotechnology company’s stock valued at $237,225,000 after purchasing an additional 13,303 shares in the last quarter. Farallon Capital Management LLC raised its stake in Ascendis Pharma A/S by 2.7% in the second quarter. Farallon Capital Management LLC now owns 1,540,000 shares of the biotechnology company’s stock valued at $177,331,000 after purchasing an additional 40,000 shares in the last quarter. Finally, Marshall Wace North America L.P. raised its stake in Ascendis Pharma A/S by 56.4% in the first quarter. Marshall Wace North America L.P. now owns 1,161,476 shares of the biotechnology company’s stock valued at $136,706,000 after purchasing an additional 418,717 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

Recommended Story: What is a CD ladder?

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.